Trade BioMarin Pharmaceutical Inc - BMRN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.55 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Biomarin Pharmaceutical Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 91.13 |
| Open* | 90.4 |
| 1-Year Change* | -8.41% |
| Day's Range* | 90.39 - 91.67 |
| 52 wk Range | 76.02-117.77 |
| Average Volume (10 days) | 1.12M |
| Average Volume (3 months) | 35.96M |
| Market Cap | 17.43B |
| P/E Ratio | 120.40 |
| Shares Outstanding | 188.37M |
| Revenue | 2.31B |
| EPS | 0.77 |
| Dividend (Yield %) | N/A |
| Beta | 0.32 |
| Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 15, 2024 | 91.13 | -0.87 | -0.95% | 92.00 | 93.30 | 90.90 |
| Apr 12, 2024 | 92.15 | 1.31 | 1.44% | 90.84 | 93.16 | 90.16 |
| Apr 11, 2024 | 91.37 | 1.44 | 1.60% | 89.93 | 91.52 | 89.20 |
| Apr 10, 2024 | 90.08 | 2.27 | 2.59% | 87.81 | 90.32 | 87.62 |
| Apr 9, 2024 | 88.88 | 2.45 | 2.83% | 86.43 | 89.11 | 86.43 |
| Apr 8, 2024 | 87.28 | 1.23 | 1.43% | 86.05 | 88.03 | 85.71 |
| Apr 5, 2024 | 86.84 | 0.84 | 0.98% | 86.00 | 87.14 | 85.46 |
| Apr 4, 2024 | 86.79 | 0.59 | 0.68% | 86.20 | 87.99 | 85.93 |
| Apr 3, 2024 | 86.67 | 0.88 | 1.03% | 85.79 | 87.65 | 85.29 |
| Apr 2, 2024 | 86.68 | 1.01 | 1.18% | 85.67 | 86.86 | 85.26 |
| Apr 1, 2024 | 87.03 | 0.75 | 0.87% | 86.28 | 87.18 | 86.02 |
| Mar 28, 2024 | 87.27 | -0.70 | -0.80% | 87.97 | 88.34 | 86.59 |
| Mar 27, 2024 | 88.38 | 0.56 | 0.64% | 87.82 | 88.68 | 87.23 |
| Mar 26, 2024 | 87.63 | 1.17 | 1.35% | 86.46 | 87.79 | 86.41 |
| Mar 25, 2024 | 86.43 | 1.88 | 2.22% | 84.55 | 86.91 | 84.30 |
| Mar 22, 2024 | 85.02 | 1.25 | 1.49% | 83.77 | 85.23 | 83.54 |
| Mar 21, 2024 | 84.03 | -0.35 | -0.41% | 84.38 | 85.06 | 83.76 |
| Mar 20, 2024 | 84.66 | 0.43 | 0.51% | 84.23 | 85.08 | 83.66 |
| Mar 19, 2024 | 85.17 | 1.85 | 2.22% | 83.32 | 85.51 | 83.32 |
| Mar 18, 2024 | 83.72 | -0.18 | -0.21% | 83.90 | 84.53 | 83.42 |
BioMarin Pharmaceutical Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, April 24, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q1 2024 Biomarin Pharmaceutical Inc Earnings Release Q1 2024 Biomarin Pharmaceutical Inc Earnings ReleaseForecast -Previous - |
| Time (UTC) 20:30 | Country US
| Event Q1 2024 Biomarin Pharmaceutical Inc Earnings Call Q1 2024 Biomarin Pharmaceutical Inc Earnings CallForecast -Previous - |
| Tuesday, May 21, 2024 | ||
| Time (UTC) 16:00 | Country US
| Event Biomarin Pharmaceutical Inc Annual Shareholders Meeting Biomarin Pharmaceutical Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, May 22, 2024 | ||
| Time (UTC) 17:00 | Country US
| Event Biomarin Pharmaceutical Inc Annual Shareholders Meeting Biomarin Pharmaceutical Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, July 29, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q2 2024 Biomarin Pharmaceutical Inc Earnings Release Q2 2024 Biomarin Pharmaceutical Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 2096.04 | 1846.28 | 1860.45 | 1704.05 | 1491.21 |
| Revenue | 2096.04 | 1846.28 | 1860.45 | 1704.05 | 1491.21 |
| Cost of Revenue, Total | 483.669 | 470.515 | 524.272 | 359.466 | 315.264 |
| Gross Profit | 1612.37 | 1375.76 | 1336.18 | 1344.58 | 1175.95 |
| Total Operating Expense | 1946.48 | 1928.62 | 1897.22 | 1804.51 | 1614.74 |
| Selling/General/Admin. Expenses, Total | 831.009 | 760.923 | 737.784 | 675.665 | 610.014 |
| Research & Development | 649.606 | 628.793 | 628.116 | 715.007 | 696.328 |
| Depreciation / Amortization | 62.8 | 61.9 | 62.2 | 53.5 | 30.3 |
| Interest Expense (Income) - Net Operating | -1.548 | -0.115 | 5.259 | -5.661 | |
| Unusual Expense (Income) | -85 | 0 | -59.495 | -25 | -50 |
| Other Operating Expenses, Total | 4.393 | 8.033 | 4.458 | 20.608 | 18.491 |
| Operating Income | 149.562 | -82.341 | -36.765 | -100.457 | -123.524 |
| Interest Income (Expense), Net Non-Operating | 2.064 | -4.855 | -12.705 | -1.299 | -21.386 |
| Other, Net | -2.05 | 11.846 | 7.148 | 6.945 | 2.205 |
| Net Income Before Taxes | 149.576 | -75.35 | -42.322 | -94.811 | -142.705 |
| Net Income After Taxes | 141.561 | -68 | 4.561 | -23.848 | -77.211 |
| Net Income Before Extra. Items | 141.561 | -68 | 4.561 | -23.848 | -77.211 |
| Net Income | 141.561 | -64.08 | 859.1 | -23.848 | -77.211 |
| Income Available to Common Excl. Extra. Items | 141.561 | -68 | 4.561 | -23.848 | -77.211 |
| Income Available to Common Incl. Extra. Items | 141.561 | -64.08 | 859.1 | -23.848 | -77.211 |
| Diluted Net Income | 141.561 | -64.08 | 859.1 | -23.848 | -77.211 |
| Diluted Weighted Average Shares | 188.963 | 182.852 | 191.678 | 179.039 | 177.061 |
| Diluted EPS Excluding Extraordinary Items | 0.74915 | -0.37189 | 0.0238 | -0.1332 | -0.43607 |
| Diluted Normalized EPS | 0.32343 | -0.37189 | -0.17796 | -0.22396 | -0.61962 |
| Total Extraordinary Items | 3.92 | 854.539 | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 595.275 | 596.415 | 537.538 | 505.344 | 533.798 |
| Revenue | 595.275 | 596.415 | 537.538 | 505.344 | 533.798 |
| Cost of Revenue, Total | 128.082 | 126.549 | 127.29 | 116.288 | 123.126 |
| Gross Profit | 467.193 | 469.866 | 410.248 | 389.056 | 410.672 |
| Total Operating Expense | 536.405 | 537.068 | 562.038 | 507.761 | 494.646 |
| Selling/General/Admin. Expenses, Total | 215.336 | 223.003 | 245.739 | 216.816 | 196.835 |
| Research & Development | 177.363 | 171.846 | 172.751 | 157.829 | 158.19 |
| Depreciation / Amortization | 15.6 | 15.7 | 15.7 | 15.9 | 15.6 |
| Unusual Expense (Income) | 0 | 0 | 0 | 0 | 0 |
| Other Operating Expenses, Total | 0.024 | -0.03 | 0.558 | 0.928 | 0.895 |
| Operating Income | 58.87 | 59.347 | -24.5 | -2.417 | 39.152 |
| Interest Income (Expense), Net Non-Operating | 8.857 | 8.24 | 5.084 | 0.32 | -1.354 |
| Other, Net | 3.083 | -10.83 | 1.858 | 0.193 | -2.947 |
| Net Income Before Taxes | 70.81 | 56.757 | -17.558 | -1.904 | 34.851 |
| Net Income After Taxes | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
| Net Income Before Extra. Items | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
| Net Income | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
| Income Available to Common Excl. Extra. Items | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
| Income Available to Common Incl. Extra. Items | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
| Diluted Net Income | 56.04 | 50.852 | -0.249 | -6.652 | 27.664 |
| Diluted Weighted Average Shares | 194.998 | 194.363 | 186.037 | 185.597 | 187.448 |
| Diluted EPS Excluding Extraordinary Items | 0.28739 | 0.26163 | -0.00134 | -0.03584 | 0.14758 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 0.28739 | 0.26163 | -0.00134 | -0.03584 | 0.14758 |
| Total Extraordinary Items |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 2751.46 | 2274.39 | 2342.22 | 1942.14 | 2056.22 |
| Cash and Short Term Investments | 1291.54 | 1013.88 | 1065.39 | 753.807 | 1084.31 |
| Cash & Equivalents | 724.531 | 587.276 | 649.158 | 437.446 | 493.982 |
| Short Term Investments | 567.006 | 426.599 | 416.228 | 316.361 | 590.326 |
| Total Receivables, Net | 461.316 | 373.399 | 448.351 | 377.404 | 342.633 |
| Accounts Receivable - Trade, Net | 461.316 | 373.399 | 448.351 | 377.404 | 342.633 |
| Total Inventory | 894.083 | 776.669 | 698.548 | 680.275 | 530.871 |
| Other Current Assets, Total | 104.521 | 110.442 | 129.934 | 130.657 | 98.403 |
| Total Assets | 6375.07 | 6003.33 | 5848.02 | 4690.04 | 4427.13 |
| Property/Plant/Equipment, Total - Net | 1114.32 | 1081.88 | 1089.58 | 1070.3 | 948.682 |
| Property/Plant/Equipment, Total - Gross | 1916.47 | 1802.45 | 1725.18 | 1619.4 | 1421.32 |
| Accumulated Depreciation, Total | -802.145 | -720.574 | -635.595 | -549.1 | -472.635 |
| Goodwill, Net | 196.199 | 196.199 | 196.199 | 197.039 | 197.039 |
| Intangibles, Net | 338.569 | 388.652 | 417.271 | 456.58 | 491.808 |
| Long Term Investments | 333.835 | 507.793 | 285.473 | 411.978 | 235.864 |
| Other Long Term Assets, Total | 1640.69 | 1554.42 | 1517.28 | 611.997 | 497.52 |
| Total Current Liabilities | 588.884 | 539.822 | 492.548 | 932.503 | 523.241 |
| Payable/Accrued | 231.238 | 193.003 | 191.429 | 240.981 | 208.119 |
| Accrued Expenses | 317.834 | 277.059 | 266.254 | 287.878 | 213.03 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2.287 | 2.266 | 2.865 | 365.131 | 0 |
| Other Current Liabilities, Total | 37.525 | 67.494 | 32 | 38.513 | 102.092 |
| Total Liabilities | 1771.92 | 1732.58 | 1742.02 | 1567.66 | 1459.19 |
| Total Long Term Debt | 1083.2 | 1081.04 | 1079.15 | 492.946 | 830.417 |
| Long Term Debt | 1083.02 | 1079.08 | 1075.15 | 486.238 | 830.417 |
| Deferred Income Tax | |||||
| Other Liabilities, Total | 99.831 | 111.726 | 170.319 | 142.209 | 105.53 |
| Total Equity | 4603.16 | 4270.74 | 4106 | 3122.38 | 2967.94 |
| Common Stock | 0.186 | 0.184 | 0.182 | 0.18 | 0.178 |
| Additional Paid-In Capital | 5404.9 | 5191.5 | 4993.41 | 4832.71 | 4669.93 |
| Retained Earnings (Accumulated Deficit) | -789.199 | -925.689 | -861.609 | -1720.71 | -1694.13 |
| Other Equity, Total | -0.633 | 6.116 | -29.867 | 6.638 | -6.113 |
| Total Liabilities & Shareholders’ Equity | 6375.07 | 6003.33 | 5848.02 | 4690.04 | 4427.13 |
| Total Common Shares Outstanding | 186.251 | 183.913 | 181.741 | 179.838 | 178.253 |
| Unrealized Gain (Loss) | -12.093 | -1.373 | 3.889 | 3.565 | -1.917 |
| Capital Lease Obligations | 0.184 | 1.96 | 4.006 | 6.708 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 2955.31 | 2950.12 | 2842.1 | 2751.46 | 2682.7 |
| Cash and Short Term Investments | 1125.84 | 1170.96 | 1152.09 | 1291.54 | 1273.77 |
| Cash & Equivalents | 785.414 | 694.381 | 580.074 | 724.531 | 761.515 |
| Short Term Investments | 340.431 | 476.577 | 572.017 | 567.006 | 512.253 |
| Total Receivables, Net | 572.498 | 610.222 | 597.913 | 461.316 | 419.622 |
| Accounts Receivable - Trade, Net | 572.498 | 610.222 | 597.913 | 461.316 | 419.622 |
| Total Inventory | 1032.16 | 975.546 | 918.921 | 894.083 | 839.46 |
| Other Current Assets, Total | 224.806 | 193.391 | 173.18 | 104.521 | 149.851 |
| Total Assets | 6758.16 | 6563.17 | 6433.69 | 6375.07 | 6264.04 |
| Property/Plant/Equipment, Total - Net | 1067.16 | 1067.28 | 1068.14 | 1114.32 | 1051.82 |
| Property/Plant/Equipment, Total - Gross | 1918.61 | 1896.45 | 1875.09 | 1916.47 | 1834.22 |
| Accumulated Depreciation, Total | -851.453 | -829.177 | -806.944 | -802.145 | -782.399 |
| Goodwill, Net | 196.199 | 196.199 | 196.199 | 196.199 | 196.199 |
| Intangibles, Net | 302.476 | 310.343 | 325.989 | 338.569 | 354.024 |
| Long Term Investments | 548.002 | 385.777 | 340.635 | 333.835 | 372.302 |
| Other Long Term Assets, Total | 1689.02 | 1653.46 | 1660.62 | 1640.69 | 1606.99 |
| Total Current Liabilities | 1163.22 | 597.231 | 598.231 | 588.884 | 521.02 |
| Payable/Accrued | 301.369 | 277.944 | 264.778 | 231.238 | 207.165 |
| Accrued Expenses | 350.452 | 291.027 | 307.568 | 317.834 | 264.051 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 18.004 | 28.26 | 25.885 | 37.525 | 49.804 |
| Total Liabilities | 1861.27 | 1780.34 | 1774.65 | 1771.92 | 1695.53 |
| Total Long Term Debt | 592.586 | 1084.99 | 1084.01 | 1083.2 | 1082.03 |
| Long Term Debt | 592.586 | 1084.99 | 1084.01 | 1083.02 | 1082.03 |
| Other Liabilities, Total | 105.457 | 98.12 | 92.415 | 99.831 | 92.473 |
| Total Equity | 4896.9 | 4782.83 | 4659.04 | 4603.16 | 4568.51 |
| Common Stock | 0.188 | 0.188 | 0.188 | 0.186 | 0.186 |
| Additional Paid-In Capital | 5542.77 | 5493.96 | 5417.87 | 5404.9 | 5335.85 |
| Retained Earnings (Accumulated Deficit) | -641.929 | -682.307 | -738.347 | -789.199 | -788.949 |
| Unrealized Gain (Loss) | -7.328 | -8.582 | -8.075 | -12.093 | -15.12 |
| Other Equity, Total | 3.192 | -20.428 | -12.596 | -0.633 | 36.544 |
| Total Liabilities & Shareholders’ Equity | 6758.16 | 6563.17 | 6433.69 | 6375.07 | 6264.04 |
| Total Common Shares Outstanding | 188.339 | 188.152 | 187.601 | 186.251 | 185.824 |
| Current Port. of LT Debt/Capital Leases | 493.398 | 2.287 | |||
| Capital Lease Obligations | 0.184 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 141.561 | -64.08 | 859.1 | -23.848 | -77.211 |
| Cash From Operating Activities | 175.902 | 304.536 | 85.365 | 48.262 | 20.208 |
| Cash From Operating Activities | 101.969 | 108.039 | 105.172 | 105.3 | 95.671 |
| Deferred Taxes | -52.087 | -15.608 | -888.907 | -82.76 | -68.378 |
| Non-Cash Items | 80.842 | 210.151 | 234.417 | 150.662 | 119.546 |
| Cash Taxes Paid | 54.372 | 18.153 | 8.977 | 9.726 | 16.676 |
| Cash Interest Paid | 10.281 | 10.395 | 12.178 | 8.552 | 11.623 |
| Changes in Working Capital | -96.383 | 66.034 | -224.417 | -101.092 | -49.42 |
| Cash From Investing Activities | -20.029 | -366.313 | -53.621 | -31.026 | 264.351 |
| Capital Expenditures | -131.54 | -119.225 | -137.519 | -163.406 | -144.62 |
| Other Investing Cash Flow Items, Total | 111.511 | -247.088 | 83.898 | 132.38 | 408.971 |
| Cash From Financing Activities | -18.65 | -0.048 | 181.118 | -74.674 | -388.007 |
| Financing Cash Flow Items | -85.378 | -46.203 | -44.638 | -101.198 | -80.542 |
| Issuance (Retirement) of Stock, Net | 69.333 | 49.194 | 21.913 | 31.611 | 67.488 |
| Foreign Exchange Effects | 0.032 | -0.057 | -1.15 | 0.902 | -0.598 |
| Net Change in Cash | 137.255 | -61.882 | 211.712 | -56.536 | -104.046 |
| Issuance (Retirement) of Debt, Net | -2.605 | -3.039 | 203.843 | -5.087 | -374.953 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 50.852 | 141.561 | 141.81 | 148.462 | 120.798 |
| Cash From Operating Activities | -73.932 | 175.902 | 169.116 | 10.795 | -45.431 |
| Cash From Operating Activities | 26.421 | 101.969 | 77.416 | 52.614 | 27.343 |
| Deferred Taxes | -6.36 | -52.087 | -0.743 | 3.455 | 4.8 |
| Non-Cash Items | 71.797 | 80.842 | 33.872 | -18.97 | -61.68 |
| Cash Taxes Paid | 4.364 | 54.372 | 13.425 | 11.821 | 1.316 |
| Cash Interest Paid | 1.437 | 10.281 | 6.575 | 5.137 | 1.422 |
| Changes in Working Capital | -216.642 | -96.383 | -83.239 | -174.766 | -136.692 |
| Cash From Investing Activities | -30.012 | -20.029 | 34.681 | 58.083 | 87.782 |
| Capital Expenditures | -24.766 | -131.54 | -95.181 | -58.71 | -30.675 |
| Other Investing Cash Flow Items, Total | -5.246 | 111.511 | 129.862 | 116.793 | 118.457 |
| Cash From Financing Activities | -40.742 | -18.65 | -29.519 | -37.06 | -25.28 |
| Financing Cash Flow Items | -60.897 | -85.378 | -71.75 | -65.431 | -32.949 |
| Issuance (Retirement) of Stock, Net | 21.169 | 69.333 | 43.866 | 29.493 | 8.235 |
| Issuance (Retirement) of Debt, Net | -1.014 | -2.605 | -1.635 | -1.122 | -0.566 |
| Foreign Exchange Effects | 0.229 | 0.032 | -0.039 | 0.708 | 1.093 |
| Net Change in Cash | -144.457 | 137.255 | 174.239 | 32.526 | 18.164 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
BioMarin Company profile
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.
Equity composition
Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.
| Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
Income Statement
- Annual
- Quarterly
News
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024
Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com